A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto09/28/2012 - 09/27/2021 (PI)
Millennium Pharmaceuticals, Inc.
A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis03/01/2012 - 02/28/2021 (PI)
Celgene Corporation
Molecular Imaging of Primary Amyloid Cardiomyopathy04/01/2017 - 03/31/2020 (Co-Investigator)
The Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-04
A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium
Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis09/04/2012 - 09/09/2019 (Subcontract PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc
A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.
A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of01/06/2016 - 01/05/2019 (Co-Investigator)
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.
Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.
Showing 10 of 14 results.
Show All Results
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma03/01/2010 - 03/09/2013 (PI)
Onyx Pharmaceuticals, Inc.
A MulticenterPhase II Trial of Velcade, Melphalan, and Dexamethasone (V-MD) in Patients with AL Amyloidosis or LCDD11/10/2008 - 11/09/2010 (PI)
Millennium Pharmaceuticals, Inc.
An Open Label, Phase 1/2 Study of Velcade (bortezomib) for Injection in Subjects with Light Chain Amyloidosis05/09/2005 - 08/31/2010 (PI)
Johnson & Johnson
Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell02/13/2008 - 02/12/2010 (PI)
Millennium Pharmaceuticals, Inc.
CAEL-101 301: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta09/23/2020 - 09/30/2040 (PI)
Caelum Biosciences, Inc.
CAEL-101 302: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta09/23/2020 - 09/30/2040 (PI)
Caelum Biosciences, Inc.
NEOD001-301: A Phase 3, Randomized, Multicenter, Double-Blin06/23/2021 - 06/22/2024 (PI)
Prothena Biosciences Limited
STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis12/01/2020 - 11/30/2023 (PI)
Sorrento Therapeutics, Inc.
A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…04/23/2020 - 04/22/2023 (PI)
Karyopharm Therapeutics Inc.
DARATUMUMAB, POMALIDOMIDE AND DEXAMETHASONE (DPd) IN RELAPSED/ REFRACTORY LIGHT CHAIN AMYLOIDOSIS PATIENTS PREVIOUSLY EXPOSED TO DARATUMUMAB07/23/2020 - 01/22/2023 (PI)
Weill Cornell Medical College Janssen Scientific A
DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…12/23/2019 - 12/22/2022 (PI)
Dana Farber Millennium Pharmaceu
Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…11/21/2019 - 11/20/2022 (PI)
Oncopeptides AB
54767414AMY300111/17/2017 - 11/17/2022 (PI)
Janssen Research and Development, LLC
54767414MMY3019 DARA04/15/2019 - 04/15/2022 (PI)
Janssen Scientific Affairs LLC
Showing 10 of 15 results.
Show All Results
DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2021 (PI)
Janssen Scientific Affairs LLC
NEOD001-CL002
09/24/2015 - 09/30/2019 (PI)
Prothena Therapeutics Limited
PRONTO - Protocol NEOD001-201
05/13/2016 - 03/31/2019 (PI)
Prothena Therapeutics Limited
Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 03/31/2019 (PI)
Karmanos Cancer Center
Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited